Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women

Journal of the National Cancer Institute

Volumn 102, Issue 22, 2010, Pages 1706-1715

  Lacroix, Andrea Z ^a   Powles, Trevor ^b   Osborne, C Kent ^c   Wolter, Kevin ^e   Thompson, John R ^e   Thompson, David D ^e   Allred, D Craig ^d   Armstrong, Róisín ^e   Cummings, Steve R ^f,g   Eastell, Richard ^h   Ensrud, Kristine E ^i,j   Goss, Paul ^k   Lee, Andrew ^e   Neven, Patrick ^l   Reid, David M ^m   Curto, Madelyn ^e   Vukicevic, Slobodan ⁿ  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Parkside Oncology Clinic   (United Kingdom)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j VA MEDICAL CENTER   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁿ UNIVERSITY OF ZAGREB   (Croatia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; LASOFOXIFENE; PLACEBO; SEX HORMONE BINDING GLOBULIN;

ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; ODDS RATIO; OSTEOPOROSIS, POSTMENOPAUSAL; PRIMARY PREVENTION; PYRROLIDINES; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX HORMONE-BINDING GLOBULIN; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 78649352823     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq415     Document Type: Article

References (28)

1. UK cancer mortality statistics for females. http://info.cancerresearchuk .org/cancerstats/mortality/females/index.htm. Accessed November 6, 2009.
2. Breast Cancer Statistics. www.breastcancer.org. Accessed November 6, 2009.
3. World Health Organization. Cancer. http://www.who.int/mediacentre/ factsheets/fs297/en/index.html. Accessed November 6, 2009.
4. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101(6):384-398.
5. Jordan VC. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep. 1976;60(10):1409-1419.
6. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2(8449):282.
7. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817-824.
8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
9. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-290.
10. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary fndings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352(9122):93-97.
11. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937-947.
12. Bushnell CD, Newby LK, Goldstein LB, Lin F, Yaffe K, Simon JA. Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS). Neurology. 2004;62(6):968-970.
13. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189-2197.
14. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23): 1751-1761.
15. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125-137. (Pubitemid 44050394)
16. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
17. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology. 2004; 145(4):1996-2005.
18. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxi-fene. Menopause. 2006;13(3):377-386.
19. Cohen LA, Pittman B, Wang CX, Aliaga C, Yu L, Moyer JD. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res. 2001;61(24):8683-8688.
20. Pfzer Inc. FABLYN® (lasofoxifene tartrate) 0.5 mg Tablets Reproductive Health Drugs Advisory Committee Briefng Document.: FDA. http://www.fda .gov/ohrms/dockets/ac/08/briefng/2008-4381b1-02-Pfzer.pdf. Accessed July 14, 2009.
21. Cummings SR, Ensrud KE, Delmas PD, et al. Lasofoxifene for postmen-opausal women with osteoporosis. N Engl J Med. 2010;362(8):686-696.
22. Hochberg Y. A sharper Bonferroni procedure for multiple tests of signif-cance. Biometrika. 1988;75(4):800-802.
23. Cuzick J. Continuation of the International Breast Cancer Intervention Study (IBIS). Eur J Cancer. 1998;34(11):1647-1648.
24. Grady D, Cauley JA, Geiger MJ, et al. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst. 2008;100(12):854-861.
25. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-616.
26. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287(2):216-220.
27. Beattie MS, Costantino JP, Cummings SR, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst. 2006;98(2):110-115. 28.
28. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-282.